Johnson & Johnson (JNJ). Below are some highlights from the above linked analysis:
Company Description: Johnson & Johnson is a leader in the pharmaceutical, medical device and consumer products industries.
Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair value, see page 2 of the linked PDF for a detailed description:
1. Avg. High Yield Price
2. 20-Year DCF Price
3. Avg. P/E Price
4. Graham Number
JNJ is trading at a premium to all four valuations above. When also considering the NPV MMA Differential, the stock is trading at a 16.9% discount to its calculated fair value of $142.19. JNJ earned a Star in this section since it is trading at a fair value.
Dividend Analytical Data: In this section there are three possible Stars and three key metrics, see page 2 of the linked PDF for a detailed description:
1. Free Cash Flow Payout
2. Debt To Total Capital
3. Key Metrics
4. Dividend Growth Rate
5. Years of Div. Growth
6. Rolling 4-yr Div. > 15%
JNJ earned two Stars in this section for 2.) and 3.) above. The stock earned a Star as a result of its most recent Debt to Total Capital being less than 45%. JNJ earned a Star for having an acceptable score in at least two of the four Key Metrics measured. The company has paid a cash dividend to shareholders every year since 1944 and has increased its dividend payments for 54 consecutive years.
Dividend Income vs. MMA: Why would you assume the equity risk and invest in a dividend stock if you could earn a better return in a much less risky money market account (MMA) or Treasury bond? This section compares the earning ability of this stock with a high yield MMA. Two items are considered in this section, see page 2 of the linked PDF for a detailed description:
1. NPV MMA Diff.
2. Years to > MMA
JNJ earned a Star in this section for its NPV MMA Diff. of the $1,070. This amount is in excess of the $500 target I look for in a stock that has increased dividends as long as JNJ has. The stock's current yield of 2.71% exceeds the 1.81% estimated 20-year average MMA rate.
Peers: The company's peer group includes: The AbbVie Inc. (ABBV) with a 3.6% yield, Eli Lilly & Co. (LLY) with a 2.5% yield and Bristol-Myers Squibb Company (BMY) with a 2.8% yield.
Conclusion: JNJ earned one Star in the Fair Value section, earned two Stars in the Dividend Analytical Data section and earned one Star in the Dividend Income vs. MMA section for a total of four Stars. This quantitatively ranks JNJ as a 4-Star Strong stock.
Using my D4L-PreScreen.xls model, I determined the share price would need to increase to $168.22 before JNJ's NPV MMA Differential decreased to the $500 minimum that I look for in a stock with 54 years of consecutive dividend increases. At that price the stock would yield 1.9%.
Resetting the D4L-PreScreen.xls model and solving for the dividend growth rate needed to generate the target $500 NPV MMA Differential, the calculated rate is 3.2%. This dividend growth rate is below the 6.7% used in this analysis, thus providing a minimal margin of safety. JNJ has a risk rating of 1.50 which classifies it as a Low risk stock.
JNJ is well-positioned in the Healthcare industry with a diverse revenue and an excellent research pipeline. The company's many competitive advantages include: products that are largely immune from economic cycles, minimal reliance on any single product category (or customer), substantial financial resources and a significant global presence.
The company enjoys a position of low debt and strong cash flows. Currently its free cash flow payout of 63% is slightly above my maximum, and enjoys a low total debt to capital of 27%. The stock is currently trading below my calculated fair value of $142.19. As such, I will continue to look for opportunities to add to my position in this excellent company, as my allocation allows.
Disclaimer: Material presented here is for informational purposes only. The above quantitative stock analysis, including the Star rating, is mechanically calculated and is based on historical information. The analysis assumes the stock will perform in the future as it has in the past. This is generally never true. Before buying or selling any stock you should do your own research and reach your own conclusion. See my Disclaimer for more information.
Full Disclosure: At the time of this writing, I was long in JNJ (5.8% of my Dividend Growth Portfolio) and long ABBV. See a list of all my Dividend Growth Portfolio holdings here.
- Cisco Systems, Inc. (CSCO) Dividend Stock Analysis
- Walgreens Boots Alliance, Inc. (WBA) Dividend Stock Analysis
- Abbott Laboratories (ABT) Dividend Stock Analysis
- Raytheon Company (RTN) Dividend Stock Analysis
- United Technologies Corp. (UTX) Dividend Stock Analysis
- More Stock Analysis
Tags: JNJ, ABT, LLY, BMY,
Popular Posts - Last 7 days
I know very little about hockey, but I have always loved this quote: I skate to where the puck is going to be, not where it has been. &quo...
Any income investor will tell you that it is important for a company to sustain its dividend . However, as an investor in dividend growth st...
Linked here is a detailed quantitative analysis of Omega Healthcare Investors, Inc. (OHI). Below are some highlights from the above linked ...
Has someone near and dear to you responded with a 'I was only trying to help' after royally messing something up? Have you ever tink...
Each Sunday I highlight any notable articles that I came across over the past week. Though I may not always agree with each of the articles ...
Linked here is a detailed quantitative analysis of Target Corporation (TGT). Below are some highlights from the above linked analysis: Co...
Linked here is a detailed quantitative analysis of United Technologies Corp. (UTX). Below are some highlights from the above linked analysi...
Linked here is a detailed quantitative analysis of Pfizer Inc. (PFE). Below are some highlights from the above linked analysis: Company ...
Like many that came before me, I am on a journey to construct a portfolio that will provide me... Dividends 4 Life
Presented below are are my Dividend Growth Stocks portfolio holdings. This is not a recommendation to buy these securities. I have classifi...